Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Phase 2

Completed

Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of the Lung

First Posted Date: 2009-10-20

Last Posted Date: 2016-03-31

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 32

Registration Number: NCT00998192

Locations: 🇺🇸
Ocala Oncology Center, Ocala, Florida, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Illinois Cancer Specialists, Niles, Illinois, United States

and more 14 locations

Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer

Phase 2

Active, not recruiting

Conditions: Cervical Cancer

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: cetuximab

First Posted Date: 2009-10-16

Last Posted Date: 2023-11-14

Lead Sponsor: National Cancer Institute, Naples

Target Recruit Count: 108

Registration Number: NCT00997009

Locations: 🇮🇹
Ospedale Senatore Antonio Perrino, Brindisi, Italy
🇮🇹
Ospedale Oncologico A. Businco, Cagliari, Italy
🇮🇹
A.O. Unversitaria Policlinico, Modena, Italy

and more 11 locations

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Metastatic Cancer
Ovarian Cancer
Peritoneal Cavity Cancer

Interventions: Drug: cisplatin
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2009-10-12

Last Posted Date: 2023-08-28

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 275

Registration Number: NCT00993655

Locations: 🇺🇸
Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States
🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇺🇸
CoxHealth, Springfield, Missouri, United States

and more 47 locations

CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: CS-1008
Drug: Placebo
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-10-08

Last Posted Date: 2012-09-10

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 109

Registration Number: NCT00991796

Locations: 🇩🇪
Asklepios Fachkliniken Munchen Gauting, Gauting, Germany
🇩🇪
Zentrum fur Pneumologie und Thoraxchirurgie, Grobhansdorf, Germany

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Fallopian Tube Carcinoma
Fallopian Tube Carcinosarcoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Ovarian Clear Cell Adenocarcinoma
Ovarian Serous Adenocarcinoma
Ovarian Transitional Cell Carcinoma
Primary Peritoneal Serous Adenocarcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Veliparib

First Posted Date: 2009-10-05

Last Posted Date: 2021-10-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 431

Registration Number: NCT00989651

Locations: 🇺🇸
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 20 locations

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions: Biological: cixutumumab
Drug: carboplatin
Drug: paclitaxel
Biological: cetuximab

First Posted Date: 2009-09-30

Last Posted Date: 2014-09-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 140

Registration Number: NCT00986674

Locations: 🇺🇸
Greater Baltimore Medical Center, Baltimore, Maryland, United States
🇺🇸
Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States

and more 244 locations

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

First Posted Date: 2009-09-25

Last Posted Date: 2015-04-10

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 14

Registration Number: NCT00984464

Locations: 🇺🇸
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Phase 3

Active, not recruiting

Conditions: Cervical Cancer

Interventions: Drug: cisplatin
Drug: carboplatin
Radiation: intensity-modulated radiation therapy
Radiation: standard external beam radiation therapy
Drug: paclitaxel
Radiation: Optional brachytherapy boost

First Posted Date: 2009-09-21

Last Posted Date: 2024-11-26

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 236

Registration Number: NCT00980954

Locations: 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

and more 122 locations

Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: panitumumab
Drug: paclitaxel
Procedure: surgery

First Posted Date: 2009-09-17

Last Posted Date: 2022-06-15

Lead Sponsor: Radiation Therapy Oncology Group

Target Recruit Count: 71

Registration Number: NCT00979212

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Radiological Associates of Sacramento Medical Group, Incorporated, Sacramento, California, United States
🇺🇸
Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California, United States

and more 28 locations

AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Phase 3

Completed

Conditions: Ovarian Cancer

Interventions: Drug: liposomal doxorubicin
Drug: Bevacizumab
Drug: paclitaxel
Drug: topotecan

First Posted Date: 2009-09-15

Last Posted Date: 2022-06-21

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 361

Registration Number: NCT00976911

Locations: 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇩🇪
Klinikum Nord Frauenklinik, Nürnberg, Germany
🇧🇪
UZ Antwerpen, Edegem, Belgium

and more 114 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy